Donald E. Bobo Jr - Nov 5, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP,Strategy/Corp Development
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Nov 5, 2021
Transactions value $
-$1,054,260
Form type
4
Date filed
11/5/2021, 05:31 PM
Previous filing
Oct 8, 2021
Next filing
Dec 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $240K +11.1K +19.59% $21.76 67.4K Nov 5, 2021 Direct F1
transaction EW Common Stock Sale -$540K -4.59K -6.81% $117.68 62.9K Nov 5, 2021 Direct F1, F2
transaction EW Common Stock Sale -$754K -6.46K -10.28% $116.81 56.4K Nov 5, 2021 Direct F1, F3
holding EW Common Stock 38.2K Nov 5, 2021 401(k)
holding EW Common Stock 124K Nov 5, 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -11.1K -16.67% $0.00 55.3K Nov 5, 2021 Common Stock 11.1K $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $117.42 to $118.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $116.40 to $117.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.